title: Effects of sitagliptin on the serum creatinine in Japanese type 2 diabetes.
abstract: We found a slight elevation of serum creatinine in the subjects treated with sitagliptin for 2 years and a correlation between creatinine elevation and HbA1c reduction. These results suggest that creatinine elevation is associated with activation of incretin, most possibly with up-regulation of diuretic activity of GLP-1.
authors.affiliation: The Study Group of the Diabetes Committee, Kanagawa Physicians Association, 3F Kanagawa-ken Sogo Iryo Kaikan, 3-1 Fujimi-cho, Naka-ku, Yokohama-city, Kanagawa 231 0037, Japan. Electronic address: hec@asahi-net.email.ne.jp.
authors.forename: Hajime
authors.initials: H
authors.lastname: Maeda
authors.affiliation: The Study Group of the Diabetes Committee, Kanagawa Physicians Association, 3F Kanagawa-ken Sogo Iryo Kaikan, 3-1 Fujimi-cho, Naka-ku, Yokohama-city, Kanagawa 231 0037, Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Kubota
authors.affiliation: The Study Group of the Diabetes Committee, Kanagawa Physicians Association, 3F Kanagawa-ken Sogo Iryo Kaikan, 3-1 Fujimi-cho, Naka-ku, Yokohama-city, Kanagawa 231 0037, Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Kanamori
authors.affiliation: Department of Internal Medicine, Division of Metabolism and Endocrinology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae, Kawasaki, Kanagawa 216 8511, Japan.
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Tanaka
authors.affiliation: Department of Endocrinology and Metabolism, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama-city, Kanagawa 236 0004, Japan.
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Terauchi
authors.affiliation: The Study Group of the Diabetes Committee, Kanagawa Physicians Association, 3F Kanagawa-ken Sogo Iryo Kaikan, 3-1 Fujimi-cho, Naka-ku, Yokohama-city, Kanagawa 231 0037, Japan.
authors.forename: Ikuro
authors.initials: I
authors.lastname: Matsuba
mesh_terms: D000368:Aged; D003404:Creatinine / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy* / Q000208:ethnology; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000097:blood; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D000068900:Sitagliptin Phosphate / Q000627:therapeutic use*
chemical_list: D003404:Creatinine; D054873:Dipeptidyl-Peptidase IV Inhibitors; D052216:Glucagon-Like Peptide 1; D006442:Glycated Hemoglobin; D000068900:Sitagliptin Phosphate; C517652:hemoglobin A1c protein, human
keywords: Creatinine; Dipeptidyl peptidase-4 (DPP-4) inhibitor; HbA1c; Sitagliptin